Nonclinical Laboratory Studies: Vaginal Rings Loaded with MIV-150
Council scientists are conducting studies of vaginal rings releasing MIV-150 that might provide continuous protection from acquisition and transmission of HIV for at least one month.
Laboratory scientists at the Population Council's Center for Biomedical Research (CBR) are developing drug-loaded vaginal rings to block HIV infection in humans. The rings release MIV-150, an enzyme inhibitor that prevents infected cells from producing new virus.
Based on commercially available contraceptive products, the Council’s rings are made of either silicone rubber or a plastic material called EVA. They release MIV-150 for up 2 months, potentially providing continuous protection against HIV infection.
Using an animal model of infection, Council scientists have shown that a silicone vaginal ring loaded with MIV-150 failed to block a modified form of HIV infection in macaques (monkeys). Studies with an EVA ring that releases 5 times as much MIV-150 are planned for later this year.
MIV-150 was originally developed as a potential HIV therapy by Medivir AB and Chiron Corporation. In nonclinical tests conducted by Medivir/Chiron and confirmed by scientists at CBR, MIV-150 has shown significantly increased activity against HIV-1 primary isolates, mutants, and strains of HIV-1 resistant to other anti-HIV drugs. Extensive pharmacology and toxicology testing showed that MIV-150 is nontoxic in vitro and in vivo.
Council scientists are also preparing combination vaginal rings loaded with either MIV-150 and zinc salts or MIV-150 and a contraceptive. The MIV-150/zinc ring might provide superior protection against HIV compared to a ring loaded with MIV-150 alone; the MIV-150/contraceptive ring can be used by those women who want to be protected from both pregnancy and HIV.
An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques (abstract) (HTML)
Singer,Rachel; Mawson,Paul; Derby,Nina R.; Rodriguez,Aixa; Kizima,Larisa; Menon,Radhika; Goldman,Daniel; Kenney,Jessica; Aravantinou,Meropi; Seidor,Samantha; Gettie,Agegnehu; Blanchard,James; Piatak Jr.,Michael; Lifson,Jeffrey D.; Fernandez-Romero,Jose A.; Robbiani,Melissa; Zydowsky,Thomas M.
Science Translational Medicine 4(150)
Publication date: 2012
Location: United States
HIV and AIDS
Duration: 1/2007 - ongoing
Agegnehu Gettie (Aaron Diamond AIDS Research Center)
James Blanchard (Tulane National Primate Research Center)
Jeffrey Lifson (National Cancer Institute)
Julian Bess (National Cancer Institute)
Michael Piatak (National Cancer Institute)